Abstract:BACKGROUND: Precise recipient selection optimizes the prognosis of liver transplantation (LT) for hepatocellular carcinoma (HCC). Alpha-fetoprotein (AFP) is the most commonly used biomarker for diagnosis and prognosis of HCC in the clinical context. As a crucial molecule in methionine cycle, homocysteine (Hcy) level has been proved to be related to HCC progression and metastasis. OBJECTIVE: We aimed to explore the prognostic capacity of pre-transplant serum Hcy level in LT for HCC. METHODS: This study retrospectively enrolled 161 HCC patients who had underwent LT from donation after cardiac death (DCD) in the First Affiliated Hospital of Zhejiang University from 2015.01.01 to 2018.09.01. Pre-transplant serum Hcy level was incorporated into statistical analysis together with other clinical parameters and pathological features. RESULTS: From an overall perspective, significant difference was observed in Hcy level between recurrence (n= 61) and non-recurrence group (n= 100) though subsequent analysis showed unsatisfactory predicting performance. In the whole cohort, multivariate analysis showed that lnAFP (p= 0.010) and Milan criteria (MC, p< 0.001) were independent risk factors of HCC recurrence after LT. MA score based on MC and lnAFP performed well in predicting post-LT tumor recurrence with the AUROC at 0.836 (p< 0.001) and 3-year recurrence-free survival rate at 96.8% (p< 0.001) in the low risk group (n= 69). According to the clinical practice, serum concentration lower than 20 μg/L is considered as normal range of AFP. Elevated pre-transplant serum AFP (> 20 μg/L) predicts high HCC recurrence after LT. We further divided the 161 recipients into AFP- group (n= 77, AFP ⩽ 20 μg/L) and AFP+ group (n= 84, AFP > 20 μg/L). MA score was still well presented in the AFP+ group and the AUROC for tumor recurrence was 0.823 (p< 0.001), whereas the predicting accuracy was reduced in AFP- group (AUROC: 0.754, P< 0.001). After subsequent analysis, we found that elevated pre-transplant Hcy level (> 12.75 μmol/L) predicted increased tumor recurrence risk in AFP- group. The 3-year recurrence-free survival rates were 92.0% and 53.7% (p< 0.001) in low Hcy subgroup (n= 40) and high Hcy subgroup (n= 37) respectively. Multivariate analysis showed that Hcy (p= 0.040) and Milan criteria (p= 0.003) were independent risk factors for post-transplant tumor recurrence in AFP- group. Further combination of Hcy level and Milan criteria identified a subgroup of AFP- recipients with acceptable outcomes even though beyond Milan criteria (3-year recurrence-free survival rate: 77.7%, p< 0.001). CONCLUSION: As a classic predictor in HCC prognosis, AFP performed well in our study cohort when combined with Milan criteria. Homocysteine was an effective prognostic biomarker in LT for AFP- hepatocellular carcinoma. In recipients exceeding Milan criteria, acceptable post-transplant outcome could be seen in those with low Hcy and AFP level.

Serum total homocysteine concentration does not predict outcome in renal transplant recipients

Findings of Doppler sonography do not correlate with serum lipoprotein and total homocysteine concentrations in renal transplant recipients

Pre-transplant Serum Concentrations of Anti-Endothelial Cell Antibody in Panel Reactive Antibody Negative Renal Recipients and Its Impact on Acute Rejection

High Serum Level of the Soluble CD30 Identifies Chinese Kidney Transplant Recipients at High Risk of Unfavorable Outcome

Association of Pre-Transplant Serum Level of Anti-Endothelial Cell Antibody with Acute Rejection in Kidney Transplant Recipients

[Homocysteine, Folate Therapy and Outcome in Hemodialysis: Results from a Prospective Study].

The role of serum uric acid in the prediction of graft‐versus‐host disease in allogeneic hematopoietic stem cell transplantation

Long‐term outcome in kidney transplant patients with hepatitis C (HCV) infection

[Influence of Pre-Transplant Serum Level of Soluble CD30 on the Long-Term Survival Rates of Kidney Transplant Recipients and Grafts].

Homocysteine: A Novel Prognostic Biomarker in Liver Transplantation for Alpha-Fetoprotein- Negative Hepatocellular Carcinoma

Serum levels of soluble interleukin‐2 receptor, C‐reactive protein, neopterin, myoglobin and light chains of cardiac myosin fail to correlate with the occurrence of rejection in long‐term renal and heart transplant patients

Serum creatinine is an unreliable marker of renal function in patients undergoing heart transplantation

Serum uric acid concentration is associated with lower glomerular filtration rate in children undergoing kidney transplantation

Self-rated health predicts mortality and graft loss after kidney transplantation: a 10-year follow-up study

Homocysteine-lowering Therapy Does Not Lead to Reduction in Cardiovascular Outcomes in Chronic Kidney Disease Patients: a Meta-Analysis of Randomised, Controlled Trials

INFLUENCE OF HEPATITIS B AND HEPATITIS C VIRUS INFECTION ON THE OUTCOME OF KIDNEY TRANSPLANTATION

Hyperhomocysteinemia Predicts Renal Function Decline: a Prospective Study in Hypertensive Adults

Effect of hyperhomocysteine in patients after PCI for non-ST-segment elevation myocardial infarction, a retrospective study

Prevention of Triglyceridemia by (Non-)Anticoagulant Heparin(oids) Does Not Preclude Transplant Vasculopathy and Glomerulosclerosis

Impact of Dialysis Time on Long-term Outcomes in HLA-identical Living Donor Kidney Transplant Recipients

Altered clot formation and fibrinolysis in heart transplant recipients